Kodiak Sciences (NASDAQ:KOD) Releases Earnings Results, Beats Expectations By $0.06 EPS

Posted by Lindsey Winhoffer on Mar 29th, 2025

Kodiak Sciences (NASDAQ:KOD – Get Free Report) posted its quarterly earnings data on Thursday. The company reported ($0.84) earnings per share for the quarter, topping the consensus estimate of ($0.90) by $0.06, Zacks reports.

Kodiak Sciences Price Performance

Shares of KOD stock opened at $2.91 on Friday. The stock has a 50-day moving average of $4.85 and a 200-day moving average of $5.40. Kodiak Sciences has a one year low of $2.19 and a one year high of $11.60. The stock has a market cap of $153.14 million, a PE ratio of -0.80 and a beta of 2.26.

Analyst Ratings Changes

Separately, Jefferies Financial Group raised shares of Kodiak Sciences from a “hold” rating to a “buy” rating and set a $20.00 price objective on the stock in a research note on Monday, December 9th.

Check Out Our Latest Stock Report on KOD

Kodiak Sciences Company Profile

(Get Free Report)

Kodiak Sciences Inc, a clinical stage biopharmaceutical company, researches, develops, and commercializes therapeutics to treat retinal diseases. Its lead product candidate is tarcocimab tedromer (KSI-301), an anti-vascular endothelial growth factor antibody biopolymer that is in Phase IIb/III clinical study to treat wet age-related macular degeneration (AMD), as well as Phase III clinical study for the treatment of diabetic macular edema, naïve macular edema due to retinal vein occlusion, and non-proliferative diabetic retinopathy.